Liraglutide improves cardiac structure and function in diabetic nephropathy mice with massive proteinuria
Background
Advanced diabetic nephropathy (DN) often progresses to diabetic cardiomyopathy (DCM), a severe complication characterized by structural and functional cardiac impairments, including left ventricular hypertrophy and fibrosis, ultimately leading to heart failure. Current therapeutic strategies primarily focus on glycemic and blood pressure control, but often fail to fully mitigate the progression of DCM in patients with advanced DN. Investigating novel approaches, such as GLP-1 receptor agonists, is crucial due to their known cardiovascular benefits beyond glucose regulation, offering a potential pathway to directly address cardiac remodeling and dysfunction in this high-risk population.
Study Design
Researchers established a model of advanced diabetic nephropathy with massive proteinuria in twenty 12-week-old male spontaneous type 2 diabetic KKAy mice by feeding them a high-fat diet for 10 weeks. These mice were then randomized into a diabetic model group and a liraglutide treatment group. A normal control group consisted of 10 age-matched C57BL/6J mice on a standard chow diet. After 8 weeks of intervention, cardiac structure and function were assessed via echocardiography. Myocardial histopathological changes were examined using HE staining, Masson's trichrome staining, Sirius red staining, and transmission electron microscopy. Serum cardiac indicators were measured, and collagen I and collagen III mRNA and protein levels were quantified by RT-qPCR and Western blotting.
Results
Diabetic KKAy mice exhibited significantly elevated blood glucose and increased body weight (P<0.05), alongside disordered myocardial fibers, severe interstitial and perivascular fibrosis, and markedly upregulated myocardial expressions of collagen I and collagen III. Echocardiography revealed significant cardiac remodeling and dysfunction in diabetic mice, including increased left ventricular wall thickness, interventricular septal thickness, and left ventricular mass. They also showed a reduced left ventricular internal diameter, decreased LVEF, FS, FAC, and the E/A ratio, coupled with prolonged IVRT.
Key Findings
- Diabetic KKAy mice developed significantly elevated blood glucose and increased body weight (P<0.05).
- Diabetic mice showed severe myocardial interstitial and perivascular fibrosis with upregulated
collagen Iandcollagen III. - Echocardiography revealed increased left ventricular wall thickness, interventricular septal thickness, and left ventricular mass in diabetic mice.
- Diabetic mice exhibited reduced
LVEF,FS,FAC, andE/A ratio, indicating impaired cardiac function. - Liraglutide treatment significantly improved these cardiac pathologies and alleviated functional impairment in diabetic mice.
Why It Matters
This study provides compelling preclinical evidence that liraglutide can directly mitigate severe cardiac complications in advanced diabetic nephropathy, extending its known benefits beyond glycemic control. For individuals with diabetic cardiomyopathy secondary to kidney disease, this suggests GLP-1 receptor agonists could be a critical therapeutic addition to existing protocols, potentially slowing or reversing cardiac remodeling and improving function. The findings highlight the potential for GLP-1R agonists to be integrated into treatment strategies for diabetic heart disease, offering a new avenue for improving patient outcomes and quality of life by addressing both metabolic and cardiovascular pathologies. This could lead to refined clinical guidelines for managing diabetic nephropathy with cardiac involvement.
liraglutide
diabetic nephropathy
diabetic cardiomyopathy
cardiac function
myocardial fibrosis
glp-1 agonist